644 related articles for article (PubMed ID: 31173810)
1. Interferon-γ-dependent immune responses contribute to the pathogenesis of sclerosing cholangitis in mice.
Ravichandran G; Neumann K; Berkhout LK; Weidemann S; Langeneckert AE; Schwinge D; Poch T; Huber S; Schiller B; Hess LU; Ziegler AE; Oldhafer KJ; Barikbin R; Schramm C; Altfeld M; Tiegs G
J Hepatol; 2019 Oct; 71(4):773-782. PubMed ID: 31173810
[TBL] [Abstract][Full Text] [Related]
2. Alterations in Intestinal Microbiota Lead to Production of Interleukin 17 by Intrahepatic γδ T-Cell Receptor-Positive Cells and Pathogenesis of Cholestatic Liver Disease.
Tedesco D; Thapa M; Chin CY; Ge Y; Gong M; Li J; Gumber S; Speck P; Elrod EJ; Burd EM; Kitchens WH; Magliocca JF; Adams AB; Weiss DS; Mohamadzadeh M; Grakoui A
Gastroenterology; 2018 Jun; 154(8):2178-2193. PubMed ID: 29454797
[TBL] [Abstract][Full Text] [Related]
3. Antagonistic effects of the cytotoxic molecules granzyme B and TRAIL in the immunopathogenesis of sclerosing cholangitis.
Kellerer M; Javed S; Casar C; Will N; Berkhout LK; Schwinge D; Krebs CF; Schramm C; Neumann K; Tiegs G
Hepatology; 2024 Mar; ():. PubMed ID: 38441998
[TBL] [Abstract][Full Text] [Related]
4. Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice.
Guicciardi ME; Trussoni CE; Krishnan A; Bronk SF; Lorenzo Pisarello MJ; O'Hara SP; Splinter PL; Gao Y; Vig P; Revzin A; LaRusso NF; Gores GJ
J Hepatol; 2018 Sep; 69(3):676-686. PubMed ID: 29802947
[TBL] [Abstract][Full Text] [Related]
5. Knockdown of vimentin reduces mesenchymal phenotype of cholangiocytes in the Mdr2
Zhou T; Kyritsi K; Wu N; Francis H; Yang Z; Chen L; O'Brien A; Kennedy L; Ceci L; Meadows V; Kusumanchi P; Wu C; Baiocchi L; Skill NJ; Saxena R; Sybenga A; Xie L; Liangpunsakul S; Meng F; Alpini G; Glaser S
EBioMedicine; 2019 Oct; 48():130-142. PubMed ID: 31522982
[TBL] [Abstract][Full Text] [Related]
6. Interleukin 2 Promotes Hepatic Regulatory T Cell Responses and Protects From Biliary Fibrosis in Murine Sclerosing Cholangitis.
Taylor AE; Carey AN; Kudira R; Lages CS; Shi T; Lam S; Karns R; Simmons J; Shanmukhappa K; Almanan M; Chougnet CA; Miethke AG
Hepatology; 2018 Nov; 68(5):1905-1921. PubMed ID: 29698570
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of p16 Decreases Biliary Damage and Liver Fibrosis in the Mdr2
Kyritsi K; Francis H; Zhou T; Ceci L; Wu N; Yang Z; Meng F; Chen L; Baiocchi L; Kundu D; Kennedy L; Liangpunsakul S; Wu C; Glaser S; Alpini G
Gene Expr; 2020 Nov; 20(2):89-103. PubMed ID: 32393417
[TBL] [Abstract][Full Text] [Related]
8. Tetrahydroxylated bile acids improve cholestatic liver and bile duct injury in the Mdr2
Fuchs CD; Dixon ED; Hendrikx T; Mlitz V; Wahlström A; Ståhlman M; Scharnagl H; Stojakovic T; Binder CJ; Marschall HU; Trauner M
Hepatol Commun; 2022 Sep; 6(9):2368-2378. PubMed ID: 35691019
[TBL] [Abstract][Full Text] [Related]
9. Activated hepatic stellate cells and portal fibroblasts contribute to cholestatic liver fibrosis in MDR2 knockout mice.
Nishio T; Hu R; Koyama Y; Liang S; Rosenthal SB; Yamamoto G; Karin D; Baglieri J; Ma HY; Xu J; Liu X; Dhar D; Iwaisako K; Taura K; Brenner DA; Kisseleva T
J Hepatol; 2019 Sep; 71(3):573-585. PubMed ID: 31071368
[TBL] [Abstract][Full Text] [Related]
10. β-Adrenoceptor blockade in sclerosing cholangitis of Mdr2 knockout mice: antifibrotic effects in a model of nonsinusoidal fibrosis.
Strack I; Schulte S; Varnholt H; Schievenbusch S; Töx U; Wendland K; Steffen HM; Drebber U; Dienes HP; Odenthal M
Lab Invest; 2011 Feb; 91(2):252-61. PubMed ID: 20921947
[TBL] [Abstract][Full Text] [Related]
11. Liver infiltrating T cells regulate bile acid metabolism in experimental cholangitis.
Glaser F; John C; Engel B; Höh B; Weidemann S; Dieckhoff J; Stein S; Becker N; Casar C; Schuran FA; Wieschendorf B; Preti M; Jessen F; Franke A; Carambia A; Lohse AW; Ittrich H; Herkel J; Heeren J; Schramm C; Schwinge D
J Hepatol; 2019 Oct; 71(4):783-792. PubMed ID: 31207266
[TBL] [Abstract][Full Text] [Related]
12. Tumour necrosis factor alpha impairs function of liver derived T lymphocytes and natural killer cells in patients with primary sclerosing cholangitis.
Bo X; Broome U; Remberger M; Sumitran-Holgersson S
Gut; 2001 Jul; 49(1):131-41. PubMed ID: 11413121
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of hepatic stem cell factor by Vivo-Morpholino treatment inhibits mast cell migration and decreases biliary damage/senescence and liver fibrosis in Mdr2
Meadows V; Kennedy L; Hargrove L; Demieville J; Meng F; Virani S; Reinhart E; Kyritsi K; Invernizzi P; Yang Z; Wu N; Liangpunsakul S; Alpini G; Francis H
Biochim Biophys Acta Mol Basis Dis; 2019 Dec; 1865(12):165557. PubMed ID: 31521820
[TBL] [Abstract][Full Text] [Related]
14. Prolonged darkness reduces liver fibrosis in a mouse model of primary sclerosing cholangitis by miR-200b down-regulation.
Wu N; Meng F; Zhou T; Han Y; Kennedy L; Venter J; Francis H; DeMorrow S; Onori P; Invernizzi P; Bernuzzi F; Mancinelli R; Gaudio E; Franchitto A; Glaser S; Alpini G
FASEB J; 2017 Oct; 31(10):4305-4324. PubMed ID: 28634212
[TBL] [Abstract][Full Text] [Related]
15. Effects of adenovirus-induced hepatocyte damage on chronic bile duct inflammation in a sclerosing cholangitis mouse model.
Fuchs S; Bayer M; Taubert R; Manns MP; Pfeilschifter JM; Christen U; Hintermann E
Liver Int; 2019 Dec; 39(12):2330-2340. PubMed ID: 31225929
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of microRNA-24 increases liver fibrosis by enhanced menin expression in Mdr2
Hall C; Ehrlich L; Meng F; Invernizzi P; Bernuzzi F; Lairmore TC; Alpini G; Glaser S
J Surg Res; 2017 Sep; 217():160-169. PubMed ID: 28602220
[TBL] [Abstract][Full Text] [Related]
17. Dysfunction of hepatic regulatory T cells in experimental sclerosing cholangitis is related to IL-12 signaling.
Schwinge D; von Haxthausen F; Quaas A; Carambia A; Otto B; Glaser F; Höh B; Thiele N; Schoknecht T; Huber S; Steffens N; Lohse AW; Herkel J; Schramm C
J Hepatol; 2017 Apr; 66(4):798-805. PubMed ID: 27965154
[TBL] [Abstract][Full Text] [Related]
18. Administration of Human MSC-Derived Extracellular Vesicles for the Treatment of Primary Sclerosing Cholangitis: Preclinical Data in MDR2 Knockout Mice.
Angioni R; Calì B; Vigneswara V; Crescenzi M; Merino A; Sánchez-Rodríguez R; Liboni C; Hoogduijn MJ; Newsome PN; Muraca M; Russo FP; Viola A
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33238629
[TBL] [Abstract][Full Text] [Related]
19. The ectonucleotidase ENTPD1/CD39 limits biliary injury and fibrosis in mouse models of sclerosing cholangitis.
Peng ZW; Rothweiler S; Wei G; Ikenaga N; Liu SB; Sverdlov DY; Vaid KA; Longhi MS; Kuang M; Robson SC; Popov YV
Hepatol Commun; 2017 Nov; 1(9):957-972. PubMed ID: 29404503
[TBL] [Abstract][Full Text] [Related]
20. Intestinal dysbiosis augments liver disease progression via NLRP3 in a murine model of primary sclerosing cholangitis.
Liao L; Schneider KM; Galvez EJC; Frissen M; Marschall HU; Su H; Hatting M; Wahlström A; Haybaeck J; Puchas P; Mohs A; Peng J; Bergheim I; Nier A; Hennings J; Reißing J; Zimmermann HW; Longerich T; Strowig T; Liedtke C; Cubero FJ; Trautwein C
Gut; 2019 Aug; 68(8):1477-1492. PubMed ID: 30872395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]